Vifor Fresenius Medical Care Renal Pharma has licenced ex-US/Japanese/Korean rights to commercialise CR845 (difelikefalin) from Cara Therapeutics for the treatment of chronic kidney disease-associated pruritus (CKD-aP).
The rapid development of antibiotic resistance has become a major public health issue that could soon kill 10 million people annually. One promising alternative to ineffective antibiotics has been around for almost a century – bacteriophages. The microbe-killing viruses are used in medicine in Georgia, Poland and Russia, but have been neglected by western doctors. Now pressure is mounting on global health authorities to put the option back on the table.
Marc Wolff has been named Chief Financial Officer of Aldevron, a provider of plasmid DNA manufacturing, protein production and antibody discovery services. Mr. Wolff will lead the global finance and accounting team across all Aldevron sites in the U.S. and Europe.
Bioeconomy industry experts gave a mixed outlook for biomaterials in mid-May in Cologne where about 200 stakeholder joined the 11th International Conference on Bio-based Materials.
https://european-biotechnology.com/wp-content/uploads/2024/04/nova.jpeg15362048Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-05-17 09:45:372018-05-17 09:45:37Biomaterials growth and crash side by side
CAR-T cell therapy specialist Kite Pharma, now part of Gilead Sciences, has expanded its cell therapy manufacturing footprint in Europe. A 117,000 square-foot facility in Hoofddorp, the Netherlands, will be operational by 2020.
CAR-T cell developer bluebird bio Inc. has extended its potential US$1bn deal with cancer neoantigen TCR specialist MediGene by two new targets adding US$500m potential revenues to the licence agreement.
British drug maker AstraZeneca’s IL-5Ralpha blocker benralizumab did not reduce exacerbations significantly compared to placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2018-05-13_um_16.57.56.png594836Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-05-13 16:58:362018-05-13 16:58:36AZ COPD drug fails in Phase III study
Researchers target metastases
Latest NewsItalian oncologists have found a more effective tumour angiogenesis blocker which curbs metastasis and tumour growth.
Vifor Pharma in €70m pruritus drug deal
Latest NewsVifor Fresenius Medical Care Renal Pharma has licenced ex-US/Japanese/Korean rights to commercialise CR845 (difelikefalin) from Cara Therapeutics for the treatment of chronic kidney disease-associated pruritus (CKD-aP).
Fighting AMR: turning the p(h)age
BackgroundThe rapid development of antibiotic resistance has become a major public health issue that could soon kill 10 million people annually. One promising alternative to ineffective antibiotics has been around for almost a century – bacteriophages. The microbe-killing viruses are used in medicine in Georgia, Poland and Russia, but have been neglected by western doctors. Now pressure is mounting on global health authorities to put the option back on the table.
Evotec signs US$65m deal with Celgene
Latest NewsEvotec AG and Celgene Corporation have entered into a strategic drug discovery and development partnership to identify new therapeutics in oncology.
Aldevron Names Marc Wolff CFO
AppointmentsMarc Wolff has been named Chief Financial Officer of Aldevron, a provider of plasmid DNA manufacturing, protein production and antibody discovery services. Mr. Wolff will lead the global finance and accounting team across all Aldevron sites in the U.S. and Europe.
Biomaterials growth and crash side by side
Latest NewsBioeconomy industry experts gave a mixed outlook for biomaterials in mid-May in Cologne where about 200 stakeholder joined the 11th International Conference on Bio-based Materials.
Cell type switch helps colon cancer evade treatment
Latest NewsResearchers at LMU Munich have unraveled a new strategy of colon cancers to evade targeted therapies.
Kite expands cell therapy manufacturing in Europe
Latest NewsCAR-T cell therapy specialist Kite Pharma, now part of Gilead Sciences, has expanded its cell therapy manufacturing footprint in Europe. A 117,000 square-foot facility in Hoofddorp, the Netherlands, will be operational by 2020.
bluebird bio expands US$1bn deal with MediGene
Latest NewsCAR-T cell developer bluebird bio Inc. has extended its potential US$1bn deal with cancer neoantigen TCR specialist MediGene by two new targets adding US$500m potential revenues to the licence agreement.
AZ COPD drug fails in Phase III study
Latest NewsBritish drug maker AstraZeneca’s IL-5Ralpha blocker benralizumab did not reduce exacerbations significantly compared to placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD).